Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00663143 · ClinicalTrials.gov registry record
Thiazolidinediones (TZD) Bone Loss and the Effects on Bone Marrow Differentiation and Osteoblast Formation
A clinical trial, sponsored by Emory University.
- Completed
- Registry status
- 9
- Enrollment target
NCT00663143: Completed study, sponsored by Emory University.
NCT00663143 is a clinical trial that has completed, run by Emory University. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00663143 has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- 9 participants
- Enrollment target
Study Summary
Thiazolidinediones (TZDs) are a commonly used antidiabetic drugs currently used by over a million patients in the United States. Recent studies have shown that treatment with TZD may increase the risk of bone fractures. The cause of bone loss is not known. We believe that TZD may cause increased accumulation of fat in the bone marrow, which may cause decrease bone formation and weak bones. .
Interventions
- PROCEDURE Stromal Cells Sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-12 |
What the finished NCT00663143 record still lists
NCT00663143 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 9 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Stromal Cells Sample is the first listed.
NCT00663143 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00663143 about?
NCT00663143 is a clinical study titled "Thiazolidinediones (TZD) Bone Loss and the Effects on Bone Marrow Differentiation and Osteoblast Formation". Thiazolidinediones (TZDs) are a commonly used antidiabetic drugs currently used by over a million patients in the United States. Recent studies have shown that treatment with TZD may increase the risk of bone fractures. The cause of bone loss is not known. We believe that TZD may cause increased acc...
What is the current status of trial NCT00663143?
This trial is currently completed. The enrollment target is 9 participants. The study started on 2009-07. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00663143?
The interventions under investigation include: Stromal Cells Sample (PROCEDURE).
Who is sponsoring clinical trial NCT00663143?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia